Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with HER2-positive and hormone receptor-positive advanced metastatic or locally advanced breast cancer~* Post-menopausal status over 1 year~* HER2-positive as assessed by local laboratory on primary or metastatic tumor~* Hormone-receptor positive defined as estrogen receptor-positive and/or progesterone receptor-positive~* At least one measurable lesion and/or non-measurable disease evaluable according to Response Evaluation Criteria In Solid Tumors Version 1.1~Exclusion Criteria:~* Previous systemic non-hormonal anticancer therapy in the metastatic or locally advanced breast cancer setting~* Previous treatment with anti-HER2 agents for breast cancer, except trastuzumab and/or lapatinib in the neoadjuvant or adjuvant setting~* Disease progression while receiving adjuvant trastuzumab and/or lapatinib treatment~* History of persistent Grade 2 or higher hematological toxicity according to National Cancer Institute-Common Toxicity Criteria Version 4.0~* Disease-free interval from completion of adjuvant/neo-adjuvant systemic non-hormonal treatment to recurrence of within 6 months~* Other malignancies within the last 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma~* Clinical or radiographic evidence of central nervous system metastases or significant cardiovascular disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy (Type: EXPERIMENTAL): Participants will receive pertuzumab in combination with trastuzumab plus aromatase inhibitor (AI) until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.~Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion.
- Arm B: Trastuzumab + AI +/- Chemotherapy (Type: ACTIVE_COMPARATOR): Participants will receive trastuzumab plus aromatase inhibitor (AI) until predefined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.~Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).